Skip to main content

Table 1 Plasmaboost cohort characteristics (n = 184)

From: Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort

Characteristic

Median (IQR)

p valuea

AD (n = 73)

MCI (n = 32)

SCI (n = 12)

NDD (n = 31)

OND (n = 36)

AD vs. MCI/SCI

AD vs. NDD/OND

NAs

APOE ε4, No. (%)

24 (33)b

9 (28)

0 (0)

4 (13)

4 (11)

0.045

0.014

 

Female, no. (%)

36 (49)

16 (50)

7 (58)

10 (32)

19 (53)

0.89

0.20

 

Age, y

71 (68–76)

69 (64–77)

69 (62–72)

70 (66–77)

54 (35–67)c

0.50

< 0.001

 

Education, y

9 (5–12)

9 (6–12)

14 (10–15)

9 (5–15)

11 (10–14)

0.20

0.47

3 | 1 | 3 | 1 | 26

MMSE, /30

24 (20–26)d

27 (26–29)

29 (27–30)

23 (19–28)

23 (17–27)

< 0.001

0.99

6 | 1 | 0 | 4 | 26

CSF, pg/ml

 Aβ42

578 (486–703)e

885 (609–1205)

800 (689–1477)

738 (590–1049)

971 (736–1206)

< 0.001

< 0.001

3 | 4 | 4 | 0 | 19

 Aβ42/40

0.034 (0.027–0.045)e

0.065 (0.047–0.078)

0.062 (0.051–0 .072)

0.083 (0.055–0.096)

0.086 (0.048–0.097)

< 0.001

< 0.001

33 | 9 | 7 | 12 | 22

 p-tau181

82 (66–106)e

45 (34–60)

41 (39–42)

33 (26–53)

33 (26–42)

< 0.001

< 0.001

3 |4 | 4 | 0 | 19

 t-tau

630 (503–840)e

276 (229–391)

221 (200–228)

226 (170–388)

220 (144–340)

< 0.001

< 0.001

3 | 4 | 4 | 0 | 19

  1. aFisher’s exact (APOE ε4 and sex) or Kruskal–Wallis tests
  2. bAD vs. MCI (p = 0.82), SCI (p = 0.017) or NDD (p = 0.052), OND (p = 0.019), Fisher’s exact test
  3. cOND vs. AD (p < 0.001), NDD (p < 0.001), Mann–Whitney U tests with Bonferroni correction
  4. dAD vs. MCI (p < 0.001), SCI (p < 0.001), Mann–Whitney U tests with Bonferroni correction
  5. eAD vs. MCI (p < 0.05), SCI (p < 0.05) or NDD (p < 0.05), OND (p < 0.05), Mann–Whitney U tests with Bonferroni correction